Salvation as healing : John Wesley\u27s missional theology

https://place.asburyseminary.edu/ecommonsatsdissertations/1309/thumbnail.jp

MM 602 Parish: Outside the Walls

Hall, Ron and Denver Moore. Same Kind of Different as Me. Nashville, TN: Thomas Nelson, 2008. ISBN-10: 084991910X Sider, Olson, and Unruh. Churches That Make a Difference. Grand Rapids: Baker, 2002. Mentored Ministry Handbook: MM 601/602: (available as a pdf in the Virtual Classroom) Mentored Ministry Forms: (MM602 E-Forms under Mentored Ministry Resources located in the Virtual Classroom)https://place.asburyseminary.edu/syllabi/3725/thumbnail.jp

IS 501 Christian Formation: Kingdom, Church and World

Clapp, Rodney. Border Crossings. Grand Rapids, MI: Brazos Press, 2000. Jenkins, Philip. The Next Christendom: The Coming of Global Christianity. New York: Oxford UP, 2007. Snyder, Howard. Kingdom, Church, and World: Biblical Themes for Today. Wipf & Stock, 2001. (Originally published as A Kingdom Manifesto, IVP, 1985.) Snyder, Howard. Models of the Kingdom. Wipf & Stock, 2001.https://place.asburyseminary.edu/syllabi/3667/thumbnail.jp

John Wesley’s Approach to Mission

John Wesley’s theology is noted for its soteriological emphasis. Most of his life was spent in England ministering among marginalized people. Much of his practical ministry, publications, prison reform, healthcare interest, education, etc., occurred while trekking through the island. Yet, Wesley’s thoughts and writings reflect the broader world. Although he was not as swift at putting Methodist missionaries abroad as Thomas Coke would have liked, Wesley had a plan in place that took in reaching those populations that claimed other religions as their faith. Thus, he wanted “Moslems,” “Hindoos,” “Hottentots,” “Native Americans,” or more inclusive of every part of the world, the “heathen,” to have an encounter with the vital gospel of Christ. This paper explores what John Wesley had to say about these groups and his approach to bringing the gospel of Christ within their reach

Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease

International audienc

Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID.

Background Peripheral artery disease (PAD) and heart failure (HF) are each independently associated with poor outcomes. Risk factors associated with new-onset HF in patients with primary PAD are unknown. Furthermore, how the presence of HF is associated with outcomes in patients with PAD is unknown. Methods and Results This analysis examined risk relationships of HF on outcomes in patients with symptomatic PAD randomized to ticagrelor or clopidogrel as part of the EUCLID (Examining Use of Ticagrelor in Peripheral Arterial Disease) trial. Patients were stratified based on presence of HF at enrollment. Cox models were used to determine the association of HF with outcomes. A separate Cox model was used to identify risk factors associated with development of HF during follow-up. Patients with PAD and HF had over twice the rate of concomitant coronary artery disease as those without HF. Patients with PAD and HF had significantly increased risk of major adverse cardiovascular events (hazard ratio [HR], 1.31; 95% CI, 1.13-1.51) and all-cause mortality (HR, 1.39; 95% CI, 1.19-1.63). In patients with PAD, the presence of HF was associated with significantly less bleeding (HR, 0.65; 95% CI, 0.45-0.96). Characteristics associated with HF development included age ≥66 (HR, 1.29; 95% CI, 1.18-1.40 per 5 years), diabetes mellitus (HR, 1.85; 95% CI, 1.41-2.43), and weight (bidirectionally associated, ≥76 kg, HR, 0.77; 95% CI, 0.64-0.93; <76 kg, HR, 1.12; 95% CI, 1.07-1.16). Conclusions Patients with PAD and HF have a high rate of coronary artery disease with a high risk for major adverse cardiovascular events and death. These data support the possible need for aggressive treatment of (recurrent) atherosclerotic disease in PAD, especially patients with HF

CRL4^(AMBRA1) targets Elongin C for ubiquitination and degradation to modulate CRL5 signaling

Multi‐subunit cullin‐RING ligases (CRLs) are the largest family of ubiquitin E3 ligases in humans. CRL activity is tightly regulated to prevent unintended substrate degradation or autocatalytic degradation of CRL subunits. Using a proteomics strategy, we discovered that CRL4^(AMBRA1) (CRL substrate receptor denoted in superscript) targets Elongin C (ELOC), the essential adapter protein of CRL5 complexes, for polyubiquitination and degradation. We showed that the ubiquitin ligase function of CRL4^(AMBRA1) is required to disrupt the assembly and attenuate the ligase activity of human CRL5^(SOCS3) and HIV‐1 CRL5^(VIF) complexes as AMBRA1 depletion leads to hyperactivation of both CRL5 complexes. Moreover, CRL4^(AMBRA1) modulates interleukin‐6/STAT3 signaling and HIV‐1 infectivity that are regulated by CRL5^(SOCS3) and CRL5^(VIF), respectively. Thus, by discovering a substrate of CRL4^(AMBRA1), ELOC, the shared adapter of CRL5 ubiquitin ligases, we uncovered a novel CRL cross‐regulation pathway